Showing 5,021 - 5,040 results of 5,673 for search 'Paduli~', query time: 3.32s Refine Results
  1. 5021
  2. 5022
  3. 5023

    La charité chrétienne : continuité d’un milieu de mémoire québécois chez les bénévoles de la Société de Saint-Vincent-de-Paul de Québec, 1940-1980 by Louis LeBel

    Published 2007-09-01
    “…Cet article tente de mettre en lumière la pertinence d’une approche par la mémoire afin d’étudier la culture politique des Québécois en général de même que celle des bénévoles de la Société de St-Vincent-de-Paul de Québec. Tout d’abord, les implications de la mémoire collective dans la définition de la culture politique des Québécois sont mises en évidence. …”
    Get full text
    Article
  4. 5024
  5. 5025
  6. 5026
  7. 5027
  8. 5028

    Protocol for a phase IV double-blind randomised controlled trial to investigate the effect of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine on pneumococcal colonisation using the experimental human pneumococcal challenge model in healthy adults (PREVENTING PNEUMO 2) by Tao Chen, Duolao Wang, Konstantinos Liatsikos, Stephen B Gordon, Hassan Burhan, Ben Morton, Tinashe K Nyazika, Bradford D Gessner, Helen Hill, Andrea Collins, Josh Hamilton, Kelly Davies, Fred Fyles, Phoebe Hazenberg, Elizabeth Begier, Angela Hyder-Wright, Sherin Pojar, Christopher Myerscough, Jesus Reine, Ryan E Robinson, Britta Urban, Elena Mitsi, Carla Solorzano, Angela Quinn, Kaijie Pan, Annaliesa S Anderson, Christian Theilacker, Daniela M Ferreira, Kelly Convey, James Court, Madlen Farrar, Lisa Hitchins, Ashleigh Howard, Lauren Kerruish, Samuel Latham, Annabel Murphy, Elissavet Nikolaou, Angelina Peterson

    Published 2022-07-01
    “…Here, we summarise an ethically approved protocol for a double-blind, randomised controlled trial investigating the effect of the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPV23) on pneumococcal nasopharyngeal colonisation acquisition, density and duration using experimental human pneumococcal challenge (EHPC).Methods and analysis Healthy adult participants aged 18–50 years will be randomised to receive PCV13, PPV23 or placebo and then undergo one or two EHPCs involving intranasal administration of SPN at 1-month post-vaccination with serotype 3 (SPN3) and 6 months with serotype 6B (SPN6B). …”
    Get full text
    Article
  9. 5029
  10. 5030
  11. 5031
  12. 5032
  13. 5033
  14. 5034
  15. 5035
  16. 5036
  17. 5037
  18. 5038
  19. 5039
  20. 5040